ITGAM and neoplasm: Immunopathological studies demonstrated that treatment with Cas9mIL30-mPSCA NxPs prevented the intratumoral recruitment of Foxp3+ regulatory T lymphocytes (Tregs) (Fig. 8n) and nonspecific immune cells, such as F4/80+ macrophages, CD11b+Gr-1+ myeloid-derived cells (MDCs) and Ly-6G+ granulocytes, which characterize the IL30-TRAMP-C1 tumor microenvironment (TME).